 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ZW251 / Zymeworks
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_259;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.
- ZW251 / Zymeworks
Introducing ZW251, a Novel Glypican 3-Targeting Antibody Drug Conjugate Bearing a Topoisomerase 1 Inhibitor Payload () - Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_92;
All other abstracts will be released on the day of presentation. Describing Glypican-3, which is a prevalent and selective marker for hepatocellular carcinoma (HCC); Explaining the design features making ZW251 well suited to target GPC3-expressing HCC; Highlighting the preclinical characterization of ZW251 including anti-tumor activity, PK, and non-human primate toxicology
- ZW251 / Zymeworks
ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload (Section 13; Poster Board #26) - Mar 14, 2023 - Abstract #AACR2023AACR_4882;
Rapid internalization of ZW251 antibody was observed in GPC3-expressing HCC cell lines. ZW251 exhibited potent and target-specific cytotoxicity in a panel of HCC cells cultured either in monolayer or as 3D spheroids.